Cargando…

A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer

Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial. Therefore, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of anastrozole versus tamoxifen as adjuvant therapy in breast cancer. A systematic liter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yan, Pan, Wei, Tang, Xinyu, Wu, Shuqing, Sun, Xinchen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564654/ https://www.ncbi.nlm.nih.gov/pubmed/28415634 http://dx.doi.org/10.18632/oncotarget.16466

Ejemplares similares

A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
por: Lin, Ying, et al.
Publicado: (2014)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
por: Eisner, Alvin, et al.
Publicado: (2007)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
por: Mansel, R, et al.
Publicado: (2007)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer
por: Cintra, Karine A., et al.
Publicado: (2010)

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
por: Gangadhara, Sharath, et al.
Publicado: (2009)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer
por: Miller, W R, et al.
Publicado: (2002)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
por: Robertson, John FR, et al.
Publicado: (2013)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Lu, Xinli, et al.
Publicado: (2022)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes
por: Potmešil, Petr, et al.
Publicado: (2020)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Retracted: Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Corrigendum to “Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes”
Publicado: (2021)

Escitalopram co-prescription in anastrozole-treated breast cancer patients
por: Ozyurt, Hazan, et al.
Publicado: (2022)

Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study
por: Morimoto, Yoshihito, et al.
Publicado: (2017)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

The efficacy of anastrozole in subfertile men with and without abnormal testosterone to estradiol ratios
por: Yang, Yang, et al.
Publicado: (2022)

Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: A randomized controlled trial
por: Hizan, Nik Shah, et al.
Publicado: (2018)

Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
por: Hind, D, et al.
Publicado: (2007)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial
por: Acién, Pedro, et al.
Publicado: (2021)

Myocardial infarction risk and tamoxifen therapy for breast cancer
por: Geiger, A M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_aqvf69s6hiuibp5h4i7voboa56